Seed and Series A investor—the first specialist fund focused solely on treating aging as a disease—led by Laura Deming; portfolio ventures have raised >$1B and produced multiple IPOs. The firm continues to build its presence across the venture capital landscape.
Selective firm investing where it has an unfair advantage, running a company-creation platform with 22 EIRs and a 90+ C-suite council delivering market insights to healthcare, data+AI and cyber defense. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Targets hard, capital‑intensive sustainability technologies other VCs avoid, bridging solutions from developed markets into China and developing countries (energy, food, health, environment) to build traction back into developed markets. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Venture studio and fund that co‑incubates with LifePoint executives, giving startup ventures direct access to a $50B+ health system for pilot deployment, real‑world validation, and underserved population focus. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
Physician-led, immigrant-founded VC built by third-culture founders using cross-cultural insight to back healthcare founders with lived experience and target structural health inequities over generic digital tools. With a disciplined investment approach, the team drives value for both founders and investors.
NY headquarters plus offices in Accra, Cairo alongside Nairobi combine global funding-space entry with local operator proximity. A key differentiator: ex-Bridgewater/Morgan Stanley venture leaders alongside repeat backer of Africa's B2B e-commerce leaders.
Is dedicated to companies empowering informed, connected health consumers and building system-level resilience to improve outcomes, experiences, and lower healthcare costs. With a clear focus on healthcare innovation, the firm brings both capital and domain expertise.
